Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group.
Pignon B, Witz F, Desablens B, Leprise PY, Francois S, Linassier C, Berthou C, Caillot D, Lioure B, Cahn JY, Casassus P, Sadoun A, Audhuy B, Guyotat D, Briere J, Vilque JP, Baranger L, Polin V, Berthaud P, Hurteloup P, Herve P, Harousseau JL.
Pignon B, et al. Among authors: casassus p.
Br J Haematol. 1996 Aug;94(2):333-41. doi: 10.1046/j.1365-2141.1996.d01-1803.x.
Br J Haematol. 1996.
PMID: 8759894
Clinical Trial.